MX2007005470A - Compuestos tric??clicos fusionados como inhibidores del factor alfa de necrosis tumoral. - Google Patents

Compuestos tric??clicos fusionados como inhibidores del factor alfa de necrosis tumoral.

Info

Publication number
MX2007005470A
MX2007005470A MX2007005470A MX2007005470A MX2007005470A MX 2007005470 A MX2007005470 A MX 2007005470A MX 2007005470 A MX2007005470 A MX 2007005470A MX 2007005470 A MX2007005470 A MX 2007005470A MX 2007005470 A MX2007005470 A MX 2007005470A
Authority
MX
Mexico
Prior art keywords
alpha
necrosis factor
tumor necrosis
inhibitors
tricyclic compounds
Prior art date
Application number
MX2007005470A
Other languages
English (en)
Inventor
Bansi Lal
Usha Ghosh
Swati Bal-Tembe
Tulsidas More
Sapna Parikh
Somesh Sharma
Pravin Gagare
Sunil Jadhav
Shashikant Patil
Asha Kulkarni-Almeida
Radha Panicker
Anagha Damre
Ravindra Gupte
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of MX2007005470A publication Critical patent/MX2007005470A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se describen compuestos de la formula 1: (ver formula 1) en donde V es CH2; W es S(O)n; m es el numero entero 0, 1 o 2; U es O, C(O), CR13R14 o NR15; en donde R13 es H, alquilo; R14 es H, OH, OR13 o OCOR13; R15 es H, alquilo, cicloalquilo, alquenilo, C(O)R13, C(O)OR13 o alquilaminocarbonilo; R1, R2, R3, R4, R5, R6, R7 y R8 son como se definen en la presente. Estos compuestos son inhibidores del factor alfa de necrosis tumoral (TNF-() y son utiles como medicamentos para el tratamiento y prevencion de trastornos originados por la actividad incrementada de TNF-(, en particular inflamaciones.
MX2007005470A 2004-11-10 2005-11-08 Compuestos tric??clicos fusionados como inhibidores del factor alfa de necrosis tumoral. MX2007005470A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1226MU2004 2004-11-10
US63721704P 2004-12-17 2004-12-17
PCT/IB2005/053654 WO2006051477A2 (en) 2004-11-10 2005-11-08 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha

Publications (1)

Publication Number Publication Date
MX2007005470A true MX2007005470A (es) 2007-07-10

Family

ID=38654748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005470A MX2007005470A (es) 2004-11-10 2005-11-08 Compuestos tric??clicos fusionados como inhibidores del factor alfa de necrosis tumoral.

Country Status (15)

Country Link
US (3) US7834052B2 (es)
EP (1) EP1812419A2 (es)
JP (1) JP2008519824A (es)
KR (1) KR20070106981A (es)
CN (1) CN101076525B (es)
AR (1) AR056861A1 (es)
AU (1) AU2005303410B2 (es)
CA (1) CA2587671A1 (es)
IL (2) IL183038A0 (es)
MX (1) MX2007005470A (es)
NZ (1) NZ554937A (es)
RU (1) RU2406724C2 (es)
TW (1) TW200615273A (es)
WO (1) WO2006051477A2 (es)
ZA (1) ZA200703712B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
CA2772085A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human S Ervices Compounds that treat malaria and prevent malaria transmission
US8598158B2 (en) 2009-12-14 2013-12-03 Merck Sharp & Dohme Corp. Fused tricyclic compounds for the treatment of inflammatory disorders
JP5697685B2 (ja) * 2009-12-18 2015-04-08 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 三環式抗生物質
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
WO2012050918A2 (en) * 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
CN106995382A (zh) * 2016-01-25 2017-08-01 济南和润化工科技有限公司 一种催化氢化法生产3-甲基-4-氨基苯甲酸的方法
WO2017167994A1 (en) * 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
BR112018069931A2 (pt) * 2016-04-01 2019-02-05 Sanofi Sa derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
US10669286B2 (en) * 2016-04-01 2020-06-02 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
EA201892144A1 (ru) * 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
CN106831460A (zh) * 2017-02-24 2017-06-13 青铜峡市嘉华化工有限公司 3‑甲基‑4‑氨基苯甲酸的制备方法
USD817148S1 (en) * 2017-04-05 2018-05-08 Dormakaba Canada Inc. Locking system housing
CN107501106A (zh) * 2017-08-14 2017-12-22 中涛新材料有限公司 一种催化加氢制备3‑甲基‑4‑氨基苯甲酸的方法
JP7413346B2 (ja) 2019-03-06 2024-01-15 第一三共株式会社 ピロロピラゾール誘導体
CN115010621B (zh) * 2022-07-21 2023-11-03 山东百启生物医药有限公司 一种4-溴-3-甲基苯甲腈的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48807A0 (en) * 1975-02-18 1976-03-31 Syntex Inc Novel 6,11-dihydrodibenzo-thiepin-11-ones,their preparation and compositions containing them
US4130654A (en) * 1978-01-30 1978-12-19 Syntex (U.S.A.) Inc. Novel 4-(8X-6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-yl)-4-oxobutyric acids, methods of preparation, compositions and uses thereof
IL57077A0 (en) * 1978-04-21 1979-07-25 Syntex Inc 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them
GB2094790B (en) * 1981-03-13 1985-10-09 Spofa Vereinigte Pharma Werke Tricycle compounds
JPH0240662A (ja) 1988-08-01 1990-02-09 Ricoh Co Ltd 電子写真用感光体
US5036067A (en) * 1990-03-14 1991-07-30 Merck & Co., Inc. Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
JPH08119920A (ja) 1994-10-18 1996-05-14 Kyowa Hakko Kogyo Co Ltd 三環式アニリド誘導体
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
JPH11130772A (ja) 1997-10-28 1999-05-18 Kyowa Hakko Kogyo Co Ltd 含窒素複素環化合物
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
TW200614995A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Tricyclic guanidine derivatives as sodium-proton exchange inhibitors

Also Published As

Publication number Publication date
US7834052B2 (en) 2010-11-16
US20100324026A1 (en) 2010-12-23
AU2005303410A1 (en) 2006-05-18
IL210036A0 (en) 2011-02-28
KR20070106981A (ko) 2007-11-06
CN101076525A (zh) 2007-11-21
US7964631B2 (en) 2011-06-21
US20070299050A1 (en) 2007-12-27
NZ554937A (en) 2011-01-28
JP2008519824A (ja) 2008-06-12
ZA200703712B (en) 2010-04-28
AR056861A1 (es) 2007-10-31
TW200615273A (en) 2006-05-16
CN101076525B (zh) 2011-07-27
WO2006051477A2 (en) 2006-05-18
EP1812419A2 (en) 2007-08-01
CA2587671A1 (en) 2006-05-18
US20100305094A1 (en) 2010-12-02
IL183038A0 (en) 2007-09-20
US8163730B2 (en) 2012-04-24
RU2007121682A (ru) 2008-12-20
RU2406724C2 (ru) 2010-12-20
AU2005303410B2 (en) 2011-12-15
WO2006051477A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
MX2007005470A (es) Compuestos tric??clicos fusionados como inhibidores del factor alfa de necrosis tumoral.
WO2004013120A8 (en) Novel benzodioxoles
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
GB0325956D0 (en) Novel compounds
DE60330150D1 (en) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
SE0104332D0 (sv) Therapeutic agents
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
TW200504034A (en) Therapeutic agents
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
GB0413087D0 (en) Therapeutic compounds
NO20054476D0 (no) Forbindelser for behandling av smerte
DE602004011394D1 (en) Thiazolderivate
WO2005028429A3 (en) Haloalkyl containing compounds as cysteine protease inhibitors
TW200716547A (en) Piperidin-4-yl-amide derivatives
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
EP1483251A4 (en) DERIVATIVES OF C3-CYANO EPOTHILONE
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
WO2005066167A3 (en) 3-quinuclidinyl heteroatom bridged biaryl derivatives
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
BR0212899A (pt) Compostos orgânicos
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
ATE469882T1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
GB0019008D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status